We invest in what comes next

400

$400 million in funds under management

9

Portfolio Ventures

NORDELIS is a flexible and effective investment platform with international reach and presence in Finland, Switzerland, UK and USA.

Unleashing the potential of the seemingly unattainable has been the catalyst for progress throughout history.
At the heart of our purpose is the commitment to fund projects that drive forward progress for a collective benefit.

Nordelis is an expertly crafted investment vehicle designed to support ventures that resonate with our vision. Beyond providing financial backing, we bring to the table a wealth of experience and a robust network.
If your venture aspires to make a significant impact on a broader scale, we invite you to connect with us. Together we can transform ambitious possibilities into tangible achievements.

IPO

BMND

IPO

MLECW

NEWS

CLINGATE poised to establish world’s largest precision fermentation facility.

ONE MISSION

TO CHANGE THE WORLD

SYNBIO POWERLABS - CLINGATE - SYNBIO POWERHOUSE - ETERNAL - BIOMIND LABS - MOOLEC - CHARLOTTE'S WEB - NORDIQUAN -

SYNBIO POWERLABS - CLINGATE - SYNBIO POWERHOUSE - ETERNAL - BIOMIND LABS - MOOLEC - CHARLOTTE'S WEB - NORDIQUAN -

Alternative Proteins
ETERNAL
"

A food-tech company exploring fungal-based space food from a new facility at NASA Kennedy Space Center. For Earth-side applications, the ability to produce food with minimum resources can be of enormous help in disaster relief when there’s no supply chain to kickstart food production.

Learn more
Synthetic Biology
SYNBIO POWERLABS
"

A leading Biotech company catalysing the DNA-Economy by enabling the development of disruptive biotechnologies with precision fermentation, from lab-scale experiments to large-scale pilot runs. Synbio Powerlabs secured € 6.6 million funding for a unique biotechnology pilot plant for precision fermentation.

Learn more
Industrial Infrastructure & Real Estate
CLINGATE
"

Clingate is playing a pivotal role in Finland's biotechnology landscape. It is managing large industrial equipment to catalyze advancements in biotechnology.Clingate is the solution to empower researchers, laboratories, and industries to propel real breakthroughs in the field..

Learn more
Synthetic Biology Hub
SYNBIO POWERHOUSE
"

Synbio Powerhouse builds connections between researchers, businesses, and investors to promote and develop Synthetic Biology in the world. As members of their ecosystem, individuals will access valuable services and receive in-depth insight into the latest trends and developments in synthetic biology.

Learn more
Food Tech
NORDIQUAN
"

The secrets of aromas revealed. Nordiquan is pioneering breakthrough technologies with AI and synthetic biology. The mission is to reinvent the most desired flavours by harnessing the nature of their essence with science and technology.

Learn more
Biotechnology
IMMENSA BIOTECH
"

Immensa Biotech is positioned at the forefront of disruption in the biotechnology sector, it specializes in pioneering new models that redefine traditional development and innovation approaches. Immensa leads in large-scale precision fermentation projects and novel food production methods. Embracing the frontiers of a new era, it thrives on all the possibilities unlocked by scientific breakthroughs and emerging technologies. As a key biotechnology and biosciences presence in the Nordics, Immensa Biotech is a driving force behind transformative changes in the global biotechnology scene.

Learn more
Molecular Farming
MOOLEC
"

A science-based ingredient company producing real animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. Moolec Science began trading on Nasdaq on January 2023, becoming the first molecular farming food-tech company trading in public markets.

Learn more
Pharmaceuticals
BIOMIND LABS
"

The next generation of pharmaceuticals aims to treat patients with neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules. In November 2022, the biotech company announced FDA Investigational New Drug clearance for its New Chemical Entity Triptax™ targeting Treatment-Resistant Depression. A Phase II Clinical Trial for its 5-MeO-DMT based BMND08 candidate for depression and anxiety in Alzheimer’s Disease is commencing in Q2 2023.

Learn more
Health Supplements
CHARLOTTE’S WEB
"

Industry-leading, vertically integrated hemp business that produces high-quality health supplements derived from phytocannabinoid extracts.

Learn more

searching the companies of tomorrow

ALEJANDRO ANTALICH

CHAIRMAN

Mr. Antalich is the former Chief Executive Officer of ICC Labs Inc. (TSXV), a pioneering Canadian company that became the first publicly traded entity in the world to sell cannabis to a federal government, effectively bridging the gap between the stigma surrounding controlled substances and regulatory bodies. Through strategic foresight, determination, commitment, responsibility, teamwork, and passion, he led ICC Labs to its successful sale to Aurora (TSX) in November 2018, a milestone $300 million transaction that positioned Aurora as a dominant force in the industry. An accomplished entrepreneur and investor, he possesses a keen commercial instinct and a visionary approach to business growth, with extensive expertise spanning the medtech, foodtech, and pharmaceutical industries. With a strong focus on innovation, biotechnology, biomedical sciences, medtech, and clinical research, Mr. Antalich currently leads Biomind Labs Inc., a Canadian publicly traded life sciences company specializing in mental health and tailored drug delivery systems targeting specific therapeutic indications. He is also at the helm of EvokAI Creative Labs Inc., another Canadian publicly traded company dedicated to developing transformational and innovative technologies for the modern healthcare sector, particularly in the area of integrated AI deep learning for brain health. In addition to these roles, he serves as the Chairman of Eternal, focusing on high-impact areas such as alternative proteins, space exploration technology, and bio-based materials, leading the transition towards a more sustainable and ethical global ecosystem, further extending his influence in the realms of biotechnology and healthcare innovation.

PAOLA DÍAZ DELLAVALLE

EXECUTIVE DIRECTOR OF SCIENCE AND INNOVATION

Ms. Díaz Dellavalle has a Ph.D in chemistry and natural molecules with more than 15 years of experience in research, development, and management in biotechnology projects. She has studies in intellectual property and competitive intelligence analysis, with vast experience in patent strategy and technology transfer, specializing in the fields of chemistry, life sciences, pharmacy and biotechnology. During her career, she has led teams of scientists and managed subcontractors for non-clinical studies and new molecule development programs.

JUAN PRESA

DIRECTOR OF LEGAL AFFAIRS

Attorney at law from the Catholic University in Uruguay, specializing in corporate, commercial and international law. Juan has worked with companies from diverse industries such as agriculture, mining, cannabis, FinTech, including listed companies both on the New York Stock Exchange and the Toronto Stock Exchange. Juan developed the business expansion of companies through South America, Asia-Pacific and Africa, and participating in mergers and acquisitions of both public and private companies, public offerings and private placement financings.

DARIO FORNERIS

SENIOR PORTFOLIO DEVELOPMENT ADVISOR

Dario Forneris is an expert business developer and design strategist with a strong background in circular economy, product development, and expert communication. With extensive experience in design, leadership, and sustainable innovation he has a Bachelor’s in Industrial Design (Honors) and a Master’s in Ecodesign (Honors). He is a passionate advocate of design methodologies applied to bio-innovation and technology development.